跳至主要内容
临床试验/EUCTR2007-001174-81-FR
EUCTR2007-001174-81-FR进行中(未招募)不适用

RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB - LAP 07

GERCOR0 个研究点目标入组 820 人开始时间: 2007年5月2日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
820

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Age older than = 18
  • 2. Patients with de novo locally advanced, histologically proven adenocarcinoma of the pancreas without distant metastases (stage III according to the UICC classification) and not considered for curative resection after pluridisciplinary discussion.
  • 3. ECOG Performance Status = 2
  • 4. Estimated life expectancy = 12 weeks
  • 5. No prior radiotherapy nor chemotherapy for any reason
  • 6. Signed informed consent form
  • 7. Polynuclear neutrophils = 1.5 x 109/L, platelets = 100 x 109/L and hemoglobin = 9 g/dL
  • 8. Total bilirubin =1.5 N (N: upper limit of normal). In patients who have had a recent biliary drain and whose bilirubin is descending, a value of = 3 N (50 µmoles/L) is acceptable.
  • 9. AST and ALT = 2.5 N, alkaline phosphatase = 5 N
  • 10. Albumin = 25 g/L
  • 11. Creatinin = 177 µmol/L (2 mg/dL)
  • 12. Female patients who are not menopausal and their partners must accept to use effective contraception throughout treatment and for 3 months after the end of treatment. All patients who are capable of becoming pregnant must take a pregnancy test which is negative within 72 hours before beginning treatment. The definition of effective contraception is left up to the decision of the investigator.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Localized stage IA to IIB or metastatic cancer (stage IV) according to UICC
  • 2. Previous chemotherapy for any reason
  • 3. Previous abdominal radiotherapy
  • 4. Allergy to one of ingredients in erlotinib
  • 5. Prior treatment with an anti-EGFR
  • 6. Cancer within the 5 years before inclusion, except for in situ cancer of the neck of the uterus or basal cell skin cancer.
  • 7. Severe infection
  • 8. Ophthalmic disease (inflammation, keratopathy or infection)
  • 9. Symptomatic coronary or cardiac insufficiency, myocardial infarction or stroke within the last 6 months.
  • 10. Unable to take oral treatments or with gastrointestinal disorders that could be associated with absorption disorders, untreated gastric or duodenal ulcer.
  • 11. Pregnancy or breast feeding
  • 12. Unable to follow for psychological, familial or geographic reasons.
  • 13. Not affiliated with a social security regime.
  • 14. Diarrhea = grade 2 and/or uncontrolled diarrhoea

研究者

发起方
GERCOR

相似试验